Business context and reporting period
This is ChromaDex Corporation’s Form 10-K for the fiscal year ended December 31, 2021, comparing results with 2020; it is not a quarterly report. The filing describes a bioscience business focused on healthy aging and NAD+ research, with TRU NIAGEN® consumer products, NIAGEN® ingredient sales, and analytical reference standards and services. The request metadata names Niagen Bioscience, Inc., but the filing identifies the registrant as ChromaDex Corporation (ticker CDXC); verify the intended issuer.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Net sales | $67.4 million | $59.3 million |
| Gross profit / gross margin | $41.5 million / 61.5% | $35.3 million / 59.5% |
| Operating expenses | $68.6 million | $55.1 million |
| Operating loss | $(27.1) million | $(19.9) million |
| Net loss | $(27.1) million | $(19.9) million |
| Basic and diluted loss per share | $(0.40) | $(0.33) |
| Cash used in operating activities | $(24.2) million | $(10.6) million |
Sales increased 14% year over year. Consumer Products generated $56.7 million (+20%); Ingredients generated $7.4 million (−19%); Analytical Reference Standards and Services generated $3.3 million (+12%). Gross margin improved about 2 percentage points, reflecting scale, product mix, and cost savings. Higher marketing and legal spending contributed to the wider operating loss: sales and marketing expense rose 35% to $28.4 million, and general and administrative expense rose 18% to $36.4 million.
At year-end, cash and cash equivalents were $28.2 million, current assets $48.9 million, current liabilities $17.6 million, and working capital (as defined by the company) $8.4 million. The company had no borrowings on its Western Alliance Bank line of credit, which was increased to $10 million and extended to November 2023. Total liabilities were $26.1 million; the balance sheet reports lease obligations, but no drawn credit-line debt. Operating cash outflow increased mainly due to the larger loss, receivables timing, and higher inventory. Financing activities provided $36.1 million, including equity issuance and option exercises.
Material changes and notable items
- TRU NIAGEN e-commerce sales grew about $7.3 million, or 21%; distribution began in more than 3,800 U.S. Walmart stores in June 2021.
- Ingredients sales fell largely because of lower demand for other ingredients and reduced NIAGEN ingredient sales, including discontinued sales to Thorne Research.
- The company raised $24.9 million net in a February 2021 private stock sale and $1.9 million net through its ATM offering; approximately $47.8 million remained available under the ATM facility at year-end.
- Inventory purchase commitments totaled $23.2 million, principally for 2022, including a commitment to purchase about $18.0 million of inventory from exclusive NR manufacturer W.R. Grace during 2022. The Grace supply agreement runs through June 2023, subject to negotiated renewal.
- One customer, related party A.S. Watson Group, represented 13.8% of 2021 sales and 39.6% of year-end trade receivables. The filing also reports $26.0 million in uninsured U.S. bank deposits.
Outlook, risks, and contingencies
Management said available cash, expected sales cash generation, and the credit line should fund projected operating plans for at least 12 months from issuance of the financial statements. The company may nevertheless seek additional capital for longer-term plans; no quantified revenue or earnings guidance is provided. It has a history of annual losses and an accumulated deficit of approximately $169.0 million.
- Litigation: A September 2021 jury verdict in the California Elysium case awarded ChromaDex about $3.0 million for unpaid ingredient purchases, while finding ChromaDex liable for $625,000 in credits/refunds and $250,000 in fraudulent-inducement damages plus $1.025 million punitive damages. In February 2022, the parties reached a settlement agreement, but Elysium disputed it and ChromaDex sought enforcement; the ultimate outcome was unresolved in the filing. Separately, a court held two licensed patents invalid in a case against Elysium; ChromaDex appealed. The company also reported patent-review proceedings and litigation involving Thorne.
- Regulatory and product-claim risk: The FDA and FTC issued warning letters concerning company statements about NR and COVID-19. The company said it removed certain posts and press releases and disputed some allegations; it did not expect the matter to be material.
- Operating risks: COVID-related international demand effects, supply-chain delays, labor and cost inflation, dependence on limited suppliers (including Grace), customer concentration, competition, dietary-supplement regulation, and reliance on TRU NIAGEN sales could affect results.
- Other contingencies: A customer, Rejuvenation Therapeutics, sought a refund of approximately $1.6 million; the company recorded a $0.5 million return liability and said it did not expect the matter to be material. A separate licensor dispute over $1.6 million plus interest was also described as not expected to be material.
Marcum LLP gave an unqualified opinion on the financial statements and reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective and said a previously disclosed material weakness had been remediated.
Important facts for investors to verify
- Confirm the intended issuer: the filing is for ChromaDex Corporation (CDXC), not the company name in the request metadata.
- Check subsequent developments and financial accounting for the Elysium settlement dispute, patent appeal, and other litigation or contingencies.
- Assess whether TRU NIAGEN growth and new retail distribution can offset elevated marketing, legal costs, and ongoing operating cash burn.
- Review liquidity against the $23.2 million inventory commitments, customer receivable concentration, and potential future financing or dilution.
- Monitor the Grace supply agreement and the availability, cost, and quality of NR supply beyond its June 2023 term.